RedHill’s Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program

The National Institutes of Health’s (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation medical countermeasures Product Development Support contract as a potential treatment for Acute Radiation Syndrome (ARS) The RNCP is tasked…

About the Author

has written 20652 stories on this site.

Copyright © 2010-2019 strategicbusinessnews.com